Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Jul 24 2018

Full Issue

Under Fire For Role In Opioid Crisis, Purdue Pharma Brings On Self-Proclaimed Rescuer Of 'America's Troubled Companies'

Steve Miller, 76, will join the company as chairman of the board. Navigating the more than 800 opioid lawsuits against the company will be among the most immediate tasks facing the new chairman.

Bloomberg: ‘Turnaround Kid’ Is Tapped To Lead OxyContin Maker's Board

Purdue Pharma LP is bringing in a famous figure in corporate restructuring as the Oxycontin maker tries to overhaul its business and distance itself from the U.S. opioid crisis. Steve Miller, 76, will become chairman of the company’s board effective Tuesday. Miller, author of a 2008 memoir titled “The Turnaround Kid: What I Learned Rescuing America’s Most Troubled Companies,” helped lead auto-parts maker Delphi Corp. through bankruptcy and served as chairman of American International Group Inc. as the insurer worked to repay its federal bailout after the financial crisis. (Hopkins and Bsak, 7/23)

In other news on the crisis —

Politico Pro: Timetable For Senate Opioid Bill May Slip

The Senate is increasingly unlikely to vote on sweeping opioid legislation by Labor Day, potentially depriving Democrats in some hard-hit states of a vote on a bill before going home to voters. The looming fight over the nomination of Supreme Court nominee Brett Kavanaugh combined with negotiations over what gets into the bill are threatening to delay a vote on the bipartisan response to the crisis, which Senate Majority Leader Mitch McConnell said was among his priorities after scrapping August recess. (Haberkorn and Ehley, 7/23)

Atlanta Journal-Constitution: How Cobb Doctors Do Their Part To Reduce Opioid Addiction

More than 2 million Americans, they say, depend on or abuse street drugs and prescription painkillers like morphine, oxycodone, or hydrocodone prescribed by doctors. Every day since his brother’s death in 2006, Scott Rose is reminded of this and the responsibility he has to his patients. (Bonds Stables, 7/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Monday, June 1
  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF